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PURPOSE: The objective of this study was to estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers; and
measure the extent to which host, family history, and cancer treatment-related factors modify the risk.
PATIENTS AND METHODS: Patients were 810 women, with stage I or II breast cancer, for whom a BRCA1 or BRCA2 mutation had been
identified in the family. Patients were followed from the initial diagnosis of cancer until contralateral mastectomy, contralateral breast
cancer, death, or last follow-up.
RESULTS: Overall, 149 subjects (18.4%) developed a contralateral breast cancer. The 15-year actuarial risk of contralateral breast
cancer was 36.1% for women with a BRCA1 mutation and was 28.5% for women with a BRCA2 mutation. Women younger than
50 years of age at the time of breast cancer diagnosis were significantly more likely to develop a contralateral breast cancer at
15 years, compared with those older than 50 years (37.6 vs 16.8%; P¼0.003). Women aged o50 years with two or more first-
degree relatives with early-onset breast cancer were at high risk of contralateral breast cancer, compared with women with fewer, or
no first-degree relatives with breast cancer (50 vs 36%; P¼0.005). The risk of contralateral breast cancer was reduced with
oophorectomy (RR 0.47; 95% CI 0.30–0.76; P¼0.002).
CONCLUSION: The risk of contralateral breast cancer risk in BRCA mutation carriers declines with the age of diagnosis and increases
with the number of first-degree relatives affected with breast cancer. Oophorectomy reduces the risk of contralateral breast cancer in
young women with a BRCA mutation.
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Women who carry a germline mutation in either the BRCA1 or the
BRCA2 gene face a high lifetime risk of breast cancer (Ford et al,
1998) and, once diagnosed with breast cancer, face a high risk of
second primary cancer in the contralateral breast (Robson et al,
1998; Verhoog et al, 1998, 2000; Haffty et al, 2002; Metcalfe et al,
2004; Brekelmans et al, 2007; Graeser et al, 2009). The 10-year
contralateral breast cancer risk has been estimated at between 13
and 40% for women with a BRCA mutation. It is important to
identify factors, which predict the risk of contralateral breast
cancer in this group of high-risk women to provide optimum
genetic counselling and to inform treatment decisions.
We have recently reported that a family history of cancer
influences breast cancer risk in women with a BRCA1 or BRCA2
mutation (Metcalfe et al, 2010). Among women with a BRCA1
mutation, the risk of breast cancer increased by 1.2-fold for each
first-degree relative with breast cancer before age 50 years
(HR¼1.21; 95% CI 0.94–1.57), and among women with a BRCA2
mutation, the risk of breast cancer increased by 1.7-fold for each
first-degree relative with breast cancer (HR¼1.65; 95% CI 1.00–
2.71). It is unclear whether family history of cancer also influences
the risk of contralateral breast cancer in these high-risk women.
Although there have been several studies that estimate the risk
of contralateral breast cancer in women with a BRCA1 or BRCA2
mutation, there has been little research on the predictors of
contralateral breast cancer risk. In 2004, we reported on the
experience of 336 women with a BRCA mutation. Since this report,
we have extended the study sample from 336 patients to 810
patients, and we have extended the mean follow-up period from
9.2 to 11.1 years. In addition, we have collected detailed
information on the family histories of the breast cancer patients.
Using this cohort, we estimate the contralateral breast cancer risks
in women with a BRCA1 or BRCA2 mutation, and we measure the
extent to which host factors, family history, and cancer treatments
modify the risk.
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sPATIENTS AND METHODS
To identify study subjects, the pedigrees of BRCA families who
were received genetic counselling at the 10 participating cancer
genetics clinics were reviewed. A family was considered to be
eligible for the study when a BRCA1 or a BRCA2 mutation was
documented in the family and at least one case of invasive breast
cancer was recorded. Eligible study subjects included all women
from these families who were diagnosed with Stage I or Stage II
breast cancer at 65 years of age or below, between 1975 and 2008.
Living and deceased women were eligible, but those with a
previous diagnosis of cancer (including breast cancer) or those
who resided outside of North America were excluded. It was not
necessary to be a proven carrier of the mutation found in the
family to be included in the study; however, affected women who
were known to be non-carriers were excluded. All study
procedures were approved by the Institutional Review Boards at
each of the participating centres.
We identified a total of 1866 breast cancer cases in 615 families.
Of the total 1866 cases of breast cancer, 417 women were excluded
because the date of diagnosis indicated on the pedigree was before
1975, and 70 women were excluded because the age of diagnosis
was above 65 years. An additional 29 women were known not to
carry the familial mutation and were therefore excluded. In total,
19 women were excluded because they had a diagnosis of other
cancer before breast cancer, and 26 women were excluded because
they were treated outside of North America.
We were able to obtain identifying information for 993 of the
remaining 1305 women (76%). An attempt was made to contact
each of these or her next-of-kin to obtain permission to review the
medical records. Overall, 19 women (or their next of kin) refused
to provide consent for the release of the medical records. The
Table 1 Characteristics of study subjects
Variable Mean (range)
Year of birth 1949.9 (1914–1981)
Age of diagnosis (years) 42.2 (21–65)
End of follow-up 2003.6 (1977–2009)
Follow-up (years) 11.5 (0.3–33.1)
Variable N (%)
Age at diagnosis (in years)
o30 49 (6.1)
30–40 308 (38.0)
40–50 299 (36.9)
50+ 154 (19.0)
Mutation
BRCA1 498 (61.5)
BRCA2 300 (37.0)
Both 12 (1.5)
Place of residence
Canada 500 (61.7)
United States 310 (38.3)
Genetic testing
Yes 711 (87.8)
No 99 (12.2)
Vital status
Living 638 (78.8)
Deceased 172 (21.5)
Cause of death
Breast cancer 147
Second malignancy 10
Other 9
Unknown 6
First-degree relative with breast cancer p50 years
0 337 (42.8)
1 307 (39.1)
2+ 144 (18.7)
Missing 20
Adopted 2
Tumor size (cm)
0–2 500 (61.7)
2±5 291 (35.9)
Missing 19 (2.4)
Grade
I 33 (4.1)
II 140 (17.3)
III 320 (39.6)
Unknown 319 (39.0)
ER status
Positive 269 (33.2)
Negative 321 (39.6)
Equivocal 19 (2.4)
Unknown 201 (24.8)
Lymph node status
Positive 287 (35.7)
Negative 518 (64.4)
Unknown 5
Histology
Medullary 61 (7.5)
Ductal 682 (84.2)
Lobular 33 (4.1)
Other/unknown 34 (4.2)
Table 1 (Continued)
Variable N (%)
Surgery
Lumpectomy 396 (48.9)
Unilateral mastectomy 417 (41.1)
Prophylactic surgery on contralateral breast
No 555 (68.5)
Yes 255 (31.5)
Chemotherapy
No 260 (32.1)
Yes 533 (65.8)
Missing 17 (2.1)
Tamoxifen
No 500 (61.8)
Yes 268 (33.1)
Missing 42 (5.1)
Oophorectomy
No 303 (37.4)
Yes 489 (60.4)
Missing 18 (2.2)
Timing of oophorectomy
Before diagnosis 40 (8.2)
After/at diagnosis 354 (72.4)
After/at contralateral BC 75 (15.3)
Missing 20 (4.0)
Radiation therapy
No 373 (46.1)
Yes 424 (52.4)
Missing 12 (1.5)
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smedical record was requested from the hospital where treatment
was received for the remaining 974 women. In 76 cases, the
hospital was not able to locate the record or did not forward the
requested documents. The medical record was obtained for the
remaining 898 women (92%).
After review of the medical records, an additional 52 women
were excluded. Of these, 32 women were excluded because tumour
stage was greater than two; 18 women were excluded because the
tumour was non-invasive (DCIS or LCIS), and 2 women were
excluded because they refused treatment. The remaining 846
women were included in the analysis. In summary, of the 1866
breast cancers, 613 were ineligible and we were able to enroll 846 of
the remaining 1253 eligible cases (68%). 177 of the 846 women
were deceased (20.9%).
Study protocol
The medical treatment records and pathology documents were
reviewed. We established whether the tumour was unilateral or
bilateral at initial diagnosis. We recorded tumour size (in cm),
nodal status (positive/negative), and tumour grade (I to III).
Where possible, we abstracted information on both mitotic and
nuclear grade. Status of ER was recorded as positive, negative,
equivocal, or unknown. We recorded the use of chemotherapy
(yes/no), tamoxifen (yes/no), and radiotherapy (yes/no). We
established whether or not the patient had undergone a bilateral
oophorectomy, and if so, the date of the operation. In some cases,
the contralateral mastectomy and/or oophorectomy were per-
formed several years after the initial surgical treatment; the dates
of these late treatments were recorded. We reviewed the dates of
diagnosis of all contralateral breast cancers reported in the cohort.
Only invasive contralateral cancers were included. No woman was
diagnosed with contralateral breast cancer after she was diagnosed
with distal metastases. Information on family history was collected
on the patients by review of the pedigree at the time of
ascertainment. Each patient was classified according to the number
of documented first-degree relatives with early-onset breast cancer
(diagnosed at or below age 50 years) as zero, one, or two or more
affected relatives.
Statistical analysis
A survival analysis was performed. We considered the woman to
be at risk for contralateral breast cancer from the date of the first
surgical procedure to the first of contralateral breast cancer,
contralateral mastectomy, death from breast or ovarian cancer,
death from another cause, or the date of last follow-up. The date of
the last follow-up was defined as date of last contact or death.
Survival curves were constructed and compared for subgroups of
women defined by age (o40; 41–50 or 450 years), family history
(number of first-degree relatives with breast cancer), and by
mutation status (BRCA1 vs BRCA2). We also compared the risk of
contralateral breast cancer for subgroups defined by each of the
four treatments individually (i.e., tamoxifen, radiotherapy, oo-
phorectomy, chemotherapy). Hazard ratios were estimated using
the Cox proportional hazards model, implemented in SAS (SAS
Institute Inc., Cary, NC, USA). In these analyses, oophorectomy
was treated as a time-dependent variable. The hazard ratios were
adjusted for age at first cancer diagnosis, mutation status (BRCA1
vs BRCA2), family history, and other treatments received.
RESULTS
A total of 846 women with complete medical information were
identified, and of these, 810 women with stage I or II breast cancer
and an intact contralateral breast were included in the current
analysis. There were 498 women from families with a BRCA1
mutation and 300 women from families with a BRCA2 mutation.
Overall, 12 women carried a mutation in both genes. In all, 87.8%
patients had the BRCA mutation confirmed by sequencing and the
remaining 12.2% had not had genetic testing but were from a
family with a known BRCA mutation. The characteristics of the
810 women (including demographics, tumour characteristics, and
treatments) are presented in Table 1.
Patients were diagnosed between 1975 and 2008. The subjects
were followed for a mean of 11.1 years (range 0.1–32.9 years). In
all, 78.8% of the subjects were alive at the time of last follow-up. In
total, 149 subjects (18.4%) were diagnosed with a contralateral
breast cancer. All contralateral cancers were confirmed with the
medical record. The mean time interval period between the
diagnosis of the first breast cancer and the diagnosis of the
contralateral breast cancer was 5.7 years (range 0.2–15 years).
In the entire sample, the 5-year actuarial risk of contralateral
breast cancer was 13.1% (95% CI 10.3–15.9%), the 10-year risk
was 22.0% (95% CI 19.2–26.8%), and the 15-year risk was 33.8%
(95% CI 28.6–39.0%). The annual risk was 2.1%. The 5-, 10-, and
15-year cumulative risks of contralateral breast cancer were
estimated for each age group and by mutation status (Table 2).
The risk of contralateral breast cancer was estimated for patient
subgroups defined by age group (Figure 1), gene (BRCA1 vs
BRCA2), number of affected first-degree relatives, and by
treatment received (surgery, chemotherapy, tamoxifen, radio-
therapy, and ovarian ablation). The univariate and multivariate
hazard ratios associated with each of these factors are presented in
Table 3. Women who were aged 50 years or above at the time of
breast cancer diagnosed experienced a significantly reduced risk of
0.8
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Figure 1 Risk of contralateral breast cancer among subjects by age at
first breast cancer diagnosis. The end points for the three survival curves are
0.416, 0.330, and 0.168, respectively.
Table 2 Cumulative risks of contralateral breast cancer
Years
from
diagnosis
All
subjects
(%)
BRCA1
(%)
BRCA2
(%)
o50 years
at diagnosis
(%)
450 years
at diagnosis
(%)
5 13.1 13.7 12.0 14.2 8.6
10 22.0 23.8 18.7 23.9 14.7
15 33.8 36.1 28.5 37.6 16.8
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scontralateral breast cancer, compared with those diagnosed younger
than age 40 years (RR 0.47; 95% CI 0.47 0.82; P¼0.008).
The risk of contralateral breast cancer also depended on the
family history of the patient. The effect of family history was only
present for women whose initial breast cancer was diagnosed at
age 49 years or below. For these women, the 15-year risks of
contralateral breast cancer were estimated to be 33.4, 39.1, and
49.7% for women with zero, one, and two or more first-degree
relatives with breast cancer diagnosed under age 50 years.
Out of 810, 489 women (60.4%) underwent bilateral oophor-
ectomy; 40 women before breast cancer diagnosis, 354 women
within the year following breast cancer surgery, and 75 women at a
later date (20 dates missing). Subjects with an oophorectomy had a
significantly lower risk of contralateral breast cancer, compared with
women without an oophorectomy (RR 0.48; 95% CI 0.27 0.82;
P¼0.002) (Table 3). The risk reduction associated with oophor-
ectomy was significant for women diagnosed with the initial breast
cancer before the age of 50 years (RR 0.39; 95% CI 0.23–0.67;
P¼0.0006), but not for those with age 50 years or older (RR 0.90;
95% CI 0.30–2.64; P¼0.84) (Table 4). For women with a BRCA1
mutation, oophorectomy was associated with a significant reduc-
tion in the risk of contralateral breast cancer in BRCA1 carriers
(RR 0.48; 95% CI 0.27–0.84; P¼0.01) (Table 5). Oophorectomy
was associated with a 51% reduction in contralateral breast cancer
risk in BRCA2 carriers, but this was not statistically significant
(P¼0.11) (Table 5). Among women with two intact ovaries and
who were under age 50 years at first diagnosis, the 15-year
cumulative incidence of contralateral breast cancer was 58%. In
addition, if a woman in this subgroup also had two or more first-
degree relatives with breast cancer, the 15-year risk was 68%.
Neither radiotherapy nor chemotherapy was associated with a
statistically significant reduction in the risk of contralateral breast
cancer. Tamoxifen use was associated with a reduced risk of
contralateral breast cancer risk in BRCA1 carriers in the univariate
analysis (RR 0.55; 95% CI 0.31–0.94; P¼0.03); but not after adjustment
for age of diagnosis and the other treatments (Table 5). Tamoxifen was
not associated with a reduction in risk in BRCA2 carriers.
DISCUSSION
Women with BRCA mutations have an extremely high lifetime risk
of developing breast cancer. In addition, the risk of contralateral
breast cancer is also elevated. In the current expanded cohort, we
estimate the 10-year contralateral breast cancer risks to be 24% for
BRCA1 carriers and 19% for BRCA2 carriers. These risks are
Table 3 Relative risks of contralateral breast cancer associated with selected factors (all subjects)
Variable Univariate RR (95% CI) P-value Multivariate
a RR (95% CI) P-value Multivariate
b RR (95% CI) P-value
Mutation
BRCA1 1.0 1.0 1.0
BRCA2 0.86 (0.62–1.20) 0.38 0.88 (0.60–1.29) 0.51 0.86 (0.61–1.22) 0.41
Age at diagnosis (years)
o40 1.0 1.0 1.0
40–49 0.78 (0.56–1.08) 0.14 0.92 (0.65–1.29) 0.61 0.91 (0.64–1.28) 0.58
X50 0.44 (0.26–0.73) 0.001 0.47 (0.27–0.82) 0.008 0.48 (0.28–0.82) 0.007
Oophorectomy
c
No 1.0 1.0 1.0
Yes 0.49 (0.32–0.77) 0.002 0.48 (0.27–0.82) 0.002 0.53 (0.34–0.84) 0.007
Chemotherapy
No 1.0 1.0
Yes 0.87 (0.63–1.19) 0.37 0.99 (0.67–1.45) 0.94
Radiation therapy
No 1.0 1.0
Yes 1.03 (0.75–1.42) 0.84 1.11 (0.79–1.55) 0.56
Tamoxifen
No 1.0 1.0 1.0
Yes 0.64 (0.44–0.93) 0.02 0.72 (0.47–1.12) 0.14 0.74 (0.49–1.11) 0.14
ER status
Negative 1.0 1.0
Positive 0.80 (0.54–1.19) 0.26 1.02 (0.64–1.62) 0.95
Grade
I/II 1.0 1.0
III 1.00 (0.62–1.61) 0.99 0.84 (0.50–1.41) 0.51
Nodal status
Negative 1.0 1.0
Positive 0.74 (0.52–1.03) 0.08 0.76 (0.51–1.12) 0.16
First-degree relative with breast cancer p50
0 1.0 1.0 1.0
1 1.27 (0.89–1.81) 0.20 1.15 (0.80–1.67) 0.45 1.19 (0.83–1.71) 0.36
2+ 1.70 (1.13–2.54) 0.01 1.86 (9.22–2.83) 0.004 1.79 (1.18–2.71) 0.006
Trend 1.30 (1.06–1.59) 0.01 1.34 (1.08–1.66) 0.008 1.33 (1.08–1.64) 0.008
aMultivariate estimates are adjusted by all variables.
bMultivariate estimates are adjusted by four variables
cTime dependent variable in the regression of Cox’s proportional
hazards model.
Predictors of contralateral breast cancer
K Metcalfe et al
1387
British Journal of Cancer (2011) 104(9), 1384–1392 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sTable 4 Relative risks of contralateral breast cancer associated with selected factors by age at diagnosis
Variable Univariate RR (95% CI) P-value Multivariate RR (95% CI) P-value
a Multivariate RR (95% CI) P-value
b
Breast cancer diagnosis under age 50
Mutation
BRCA1 1.0 1.0 1.0
BRCA2 0.92 (0.65–1.31) 0.64 0.90 (0.59–1.35) 0.59 0.88 (0.61–1.27) 0.50
Age at diagnosis (in years)
o40 1.0 1.0 1.0
40–49 0.78 (0.56–1.08) 0.13 0.93 (0.66–1.31) 0.68 0.92 (0.65–1.30) 0.63
Oophorectomy
c
No 1.0 1.0 1.0
Yes 0.45 (0.27–0.74) 0.002 0.39 (0.23–0.67) 0.0006 0.45 (0.26–0.75) 0.002
Chemotherapy
No 1.0 1.0
Yes 0.83 (0.59–1.17) 0.29 1.08 (0.72–1.63) 0.71
Radiation therapy
No 1.0 1.0
Yes 1.03 (0.73–1.45) 0.86 1.11 (0.78–1.60) 0.56
Tamoxifen
No 1.0 1.0 1.0
Yes 0.69 (0.45–1.04) 0.08 0.69 (0.42–1.11) 0.12 0.73 (0.46–1.14) 0.16
ER status
Negative 1.0 1.0
Positive 0.86 (0.57–1.32) 0.50 1.09 (0.67–1.78) 0.73
Grade
I/II 1.0 1.0
III 0.86 (0.51–1.43) 0.56 0.75 (0.43–1.31) 0.32
Nodal status
Negative 1.0 1.0
Positive 0.66 (0.46–0.95) 0.03 0.66 (0.44–1.00) 0.05
First-degree relative with breast cancer p50
0 1.0 1.0 1.0
1 1.18 (0.80–1.73) 0.40 1.08 (0.73–1.61) 0.72 1.09 (0.74–1.62) 0.65
2+ 1.95 (1.28–2.97) 0.002 2.14 (1.36–3.33) 0.0008 2.01 (1.31–3.09) 0.002
Trend 1.38 (1.11–1.71) 0.004 1.42 (1.12–1.78) 0.003 1.39 (1.11–1.74) 0.004
Breast cancer diagnosis 50 years or older
Mutation
BRCA1 1.0 1.0 1.0
BRCA2 0.91 (0.36–2.32) 0.85 0.59 (0.17–1.98) 0.39 0.95 (0.33–2.72) 0.92
Oophorectomy
c
No 1.0 1.0 1.0
Yes 1.03 (0.38–2.81) 0.95 0.90 (0.30–2.64) 0.84 1.02 (0.36–2.97) 0.97
Chemotherapy
No 1.0 1.0
Yes 0.64 (0.24–1.74) 0.38 0.32 (0.07–1.56) 0.16
Radiation therapy
No 1.0 1.0
Yes 0.71 (0.28–1.81) 0.47 0.57 (0.18–1.84) 0.35
Tamoxifen
No 1.0 1.0 1.0
Yes 0.79 (0.29–2.12) 0.63 1.13 (0.29–4.33) 0.86 0.64 (0.22–1.89) 0.42
ER status
Negative 1.0 1.0
Positive 0.91 (0.28–2.99) 0.87 0.85 (0.17–4.36) 0.84
Grade
I/II 1.0 1.0
III 2.20 (0.55–8.71) 0.26 3.33 (0.69–1.61) 0.13
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scomparable to those in the report of Brekelmans et al (2007),
which included 262 women with a BRCA mutation and comparable
to those of (Graeser et al, 2009). In the latter study, the 10-year
contralateral breast cancer risk was 23%. However, of the 1042
women included in the Graeser et al (2009), only 17% had a
documented BRCA mutation. Some of the women included in the
cohort may have had sporadic breast cancer in which the risk of
contralateral breast cancer would have been lower. In our study,
88% of the women had their mutation status confirmed, and we
excluded known sporadic cases. In addition, in the study by
Graeser et al (2009), cancers in subjects were confirmed by medical
records for 45% of the women, compared with 100% of the cancers
in the present study.
Recently, Malone and colleagues (2010) compared contralateral
breast cancer risks in women with and without BRCA mutations
(Malone et al, 2010). They included 181 women with BRCA
mutations and observed a four-fold increased risk of contralateral
breast cancer in women with a BRCA mutation compared with
those without. This equated to a 21% risk of contralateral breast
cancer at 10 years in BRCA carriers. These results support our
observations, and demonstrate the importance of knowing BRCA
status at time of initial breast cancer diagnosis when making breast
cancer treatment decisions.
It is also important to recognise the modifiers of contralateral
breast cancer in women with BRCA mutations to effectively
counsel women on their personal risk of contralateral breast
cancer and how treatments may modify this risk. To our
knowledge, ours is the first study that has reported on the
influence of family history of cancer on contralateral breast cancer
risk in women with a BRCA1 or BRCA2 mutation. Among BRCA1
carriers, each first-degree relative affected with breast cancer
before 50 years of age was associated with a 40% increase in the
risk of contralateral breast cancer. Although this observation has
never been described previously, we have shown before that family
history of cancer influences a woman’s risk of a first primary
breast cancer, most notably in women with a BRCA1 mutation
(Metcalfe et al, 2010).
We also observed differences in the risks of contralateral breast
cancer in women with a BRCA mutation according to the age at
first breast cancer diagnosis. Women diagnosed with breast cancer
younger than 40 years of age had a 15-year contralateral breast
cancer risk of 42% (annual risk 2.8%) compared with 19% risk for
women over the age of 50 years at time of diagnosis (annual risk
1.3%). These findings are consistent with those of Graeser et al
(2009). In their study of relatives of BRCA1 mutation carriers, they
reported a 25-year contralateral breast cancer risk of 63% for
women younger than 40 years of age at time of first breast cancer
(annual risk 2.5%) compared with 20% for those older than age 50
years (annual risk 0.8%) (Graeser et al, 2009).
In the current study, we did not observe a protective effect
against contralateral breast cancer associated with chemotherapy
use (RR 0.97; P¼0.9) in the entire study population or in any
subgroup. This finding contrasts with that of Reding et al (2010),
which was based on 181 women, with a BRCA mutation, who
were alive at the time of the study interview (Reding et al, 2010).
These authors reported a 50% reduction in contralateral
breast cancer associated with chemotherapy (P¼0.04). In our
study, we also included deceased cases to eliminate the potential
for survival bias.
The strongest predictor of contralateral breast cancer in women
with a BRCA mutation in this study was oophorectomy. This effect
was observed in women who were diagnosed with their initial
breast cancer under the age of 50 years (60% reduction in risk) and
was significant for those with a BRCA1 mutation (53% reduction in
risk). A recent meta-analysis was published of eight studies that
estimated the risk of first primary breast cancer in BRCA1/2
mutation carriers who were treated with prophylactic oophor-
ectomy relative to carriers who had intact ovaries (Rebbeck et al,
2009). The study included three studies that examined the breast
cancer risk reduction in BRCA2 carriers specifically. Although two
of the studies reported no significant breast cancer risk reduction
associated with prophylactic oophorectomy in BRCA2 carriers
(Eisen et al, 2005; Chang-Claude et al, 2007), the meta-analysis
suggested that prophylactic oophorectomy offered a 53% reduc-
tion in risk of first primary breast cancer (95% CI 0.26–0.84).
In the current study, we did not observe a statistically significant
reduction in contralateral breast cancer risk associated with the
use of tamoxifen. This result differs from that of a case–control
study by Gronwald et al (2006) that included 285 BRCA mutation
carriers with contralateral breast cancer and 751 matched controls,
in which tamoxifen use was associated with a contralateral
breast cancer risk reduction of 50% for BRCA1 carriers and
58% for BRCA2 carriers. However, in none of the studies was
tamoxifen associated with a risk reduction in women after
oophorectomy. In the case–control study, 10% of the women
had an oophorectomy, compared with 60% of the subjects in the
current study.
The current study has several advantages over previous studies,
including a large sample size, confirmation of cancers and all
treatments with medical records, and the inclusion of deceased
cases. All women with breast cancer in the families were identified
and those who had been diagnosed with breast cancer from 1975 to
2008 at age 65 years or younger were eligible. Some women with
breast cancer who had not received a test result were included, but
women who had tested negative were excluded. We included
untested and deceased women in the study to avoid the survivor-
ship bias that would arise if only tested women were included. In
many cases, testing was carried out several years after the
diagnosis of breast cancer and restricting the study population
to tested women would introduce survivorship bias. However,
given the presence of a documented mutation in each family, the
inclusion of untested women should not introduce significant
misclassification bias. Within our cohort, 29 women with breast
cancer were excluded because they had undergone genetic testing
Table 4 (Continued)
Variable Univariate RR (95% CI) P-value Multivariate RR (95% CI) P-value
a Multivariate RR (95% CI) P-value
b
Nodal status
Negative 1.0 1.0
Positive 1.10 (0.39–3.09) 0.86 2.00 (0.45–8.91) 0.36
First-degree relative with breast cancer p50
0 1.0 1.0 1.0
1 1.97 (0.70–5.50) 0.20 1.34 (0.40–4.56) 0.64 1.88 (0.64–5.53) 0.25
2+ 0.72 (0.14–3.57) 0.68 0.49 (0.08–3.08) 0.45 0.91 (0.18–4.64) 0.91
Trend 1.02 (0.55–1.87) 0.96 0.79 (0.36–1.74) 0.56 1.10 (0.57–2.12) 0.78
Abbreviations: CI¼confidence interval; ER¼oestrogen receptor; RR¼relative risk.
aMultivariate estimates are adjusted by all variables;
bMultivariate estimates are adjusted by
only four variables;
cTime-dependent variable in the regression of Cox’s proportional hazards model.
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sTable 5 Relative risks of contralateral breast cancer associated with selected factors by mutation
Variable Univariate RR (95% CI) P-value Multivariate RR (95% CI) P-value
a Multivariate RR (95% CI) P-value
b
BRCA1
Age at diagnosis
o40 1.0 1.0 1.0
40–49 0.62 (0.410.96) 0.03 0.72 (0.47–1.12) 0.14 0.71 (0.46–1.10) 0.13
X50 0.43 (0.22–0.84) 0.21 0.54 (0.27–1.11) 0.09 0.53 (0.27–1.06) 0.07
Oophorectomy
c
No 1.0 1.0 1.0
Yes 0.43 (0.25–0.74) 0.002 0.48 (0.27–0.84) 0.01 0.52 (0.30–0.91) 0.02
Chemotherapy
No 1.0 1.0
Yes 0.89 (0.59–1.33) 0.57 1.09 (0.68–1.74) 0.72
Radiation therapy
No 1.0 1.0
Yes 1.08 (0.72–1.61) 0.71 1.13 (0.74–1.72) 0.56
Tamoxifen
No 1.0 1.0 1.0
Yes 0.55 (0.31–0.94) 0.03 0.61 (0.33–1.13) 0.12 0.66 (0.37–1.15) 0.14
ER status
Negative 1.0 1.0
Positive 0.57 (0.31–1.07) 0.08 0.81 (0.42–1.58) 0.54
Grade
I/II 1.0 1.0
III 0.87 (0.47–1.63) 0.67 0.66 (0.34–1.28) 0.22
Nodal status
Negative 1.0 1.0
Positive 0.80 (0.51–1.25) 0.32 0.76 (0.47–1.25) 0.28
First-degree relative with breast cancer p50
0 1.0 1.0 1.0
1 1.42 (0.91–2.23) 0.13 1.34 (0.84–2.13) 0.22 1.35 (0.86–2.13) 0.19
2+ 1.80 (1.09–3.00) 0.02 1.97 (1.17–3.31) 0.01 1.94 (1.16–3.23) 0.01
Trend 1.35 (1.05–1.73) 0.02 1.40 (1.08–1.81) 0.01 1.39 (1.08–1.80) 0.01
BRCA2
Age at diagnosis (in years)
o40 1.0 1.0 1.0
40–49 1.20 (0.68–2.14) 0.53 1.73 (0.91–3.29) 0.09 1.41 (0.76–2.60) 0.28
X50 0.56 (0.25–1.27) 0.16 0.46 (0.18–1.16) 0.10 0.48 (0.19–1.18) 0.11
Oophorectomy
c
No 1.0 1.0 1.0
Yes 0.58 (0.26–1.32) 0.19 0.49 (0.21–1.17) 0.11 0.51 (0.22–1.19) 0.12
Chemotherapy
No 1.0 1.0
Yes 0.77 (0.44–1.27) 0.28 0.94 (0.44–2.05) 0.88
Radiation therapy
No 1.0 1.0
Yes 0.87 (0.51–1.50) 0.62 0.76 (0.41–1.39) 0.37
Tamoxifen
No 1.0 1.0 1.0
Yes 0.88 (0.49–1.58) 0.67 0.86 (0.43–1.73) 0.68 0.98 (0.51–1.86) 0.95
ER status
Negative 1.0 1.0
Positive 2.62 (0.92–7.50) 0.07 3.30 (1.06–10.3) 0.04
Grade
I/II 1.0 1.0
III 1.26 (0.56–2.84) 0.59 1.62 (0.68–3.84) 0.28
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mutation. However, 711 women with breast cancer were found to
have a BRCA mutation. Therefore, 740 women had genetic testing
and 29 women were non-carriers. This suggests that o4% of
women with breast cancer in families with a documented BRCA
mutation do not have the family mutation. Therefore, of the 99
women included in this study, in which genetic testing had not
been performed, we would expect that only 4 of the women (4%)
would be non-carriers. This suggests that in 810 breast cancer
cases included in this study, four of the cases (0.4%) may not have
had a BRCA mutation. There are limitations as well. Ideally, we
would conduct a prospective study based on unselected cases.
In summary, women with a BRCA mutation have a high risk of
developing a contralateral breast cancer after the diagnosis of a
first breast cancer. This risk is highest for women diagnosed with
breast cancer under the age of 50 years and for those with multiple
first-degree relatives affected with breast cancer. For women with
intact ovaries, two or more first-degree relatives with breast cancer
and who were diagnosed at age 49 years or below, the 15-year risk of
contralateral breast cancer was 68%. For these high-risk women,
both oophorectomy and contralateral mastectomy should be
discussed as a component of the treatment plan to reduce the risk
of second primary breast cancer and to prevent ovarian cancer.
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